

Supporting Information

Photoredox Catalyzed C–P Bond Forming Reactions – Visible Light Mediated Oxidative Phosphonylations of Amines

Magnus Rueping,* Shaoqun Zhu and René M. Koenigs

Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1,
D-52074 Aachen, Germany, email: magnus.rueping@rwth-aachen.de


General: Unless otherwise noted, all commercially available compounds were used as provided without further purification. Solvents used in reactions were p.A. grade and dried only if indicated. Solvents for chromatography were technical grade and distilled prior to use. Analytical thin-layer chromatography (TLC) was performed on Merck silica gel aluminum plates with F-254 indicator, visualized by irradiation with UV light. Column chromatography was performed using silica gel Merck 60 (particle size 0.063 – 0.2 mm). Solvent mixtures are understood as volume/volume.

¹H-NMR and ¹³C-NMR were recorded on a Varian VNMR 400 or Mercury 300 spectrometer in CDCl₃. Data are reported in the following order: chemical shift (δ) in ppm; multiplicities are indicated br (broadened singlet), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet); coupling constants (*J*) are in Hertz (Hz). Mass spectra (MS-EI, 70 eV) were conducted on Firma Finnigan MAT SSQ 700. IR spectra were recorded on a Perkin Elmer Spectrum 100 spectrometer and are reported in terms of frequency of absorption (cm⁻¹).

General procedure for the Photoredox Catalyzed C–P Bond Forming Reactions

In a vial the appropriate photoredox catalyst and substrate were dissolved in the solvent indicated. Subsequently, 3 equiv. of the phosphite ester were added via syringe and the reaction mixture was stirred for the time indicated under irradiation with the light source as indicated (fluorescent bulb Osram Dulux S 5W, distance app. 5 cm). The reaction was monitored via TLC (hexanes: ethyl acetate). Upon consumption of starting material the crude mixture was purified by column chromatography (hexanes: ethyl acetate) to yield the corresponding products.


Diethyl 2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate¹ 5a



was synthesized according to the general procedure (48h)

¹H NMR (300 MHz, CDCl₃): δ = 7.31-7.29 (m, 1H), 7.20-7.09 (m, 5H), 6.91 (d, 2H, *J* = 8.1 Hz), 6.72 (t, 1H, *J* = 7.3 Hz), 5.11 (d, 1H, *J* = 20.1 Hz), 4.05-3.78 (m, 5H), 3.60-3.52 (m, 1H), 3.05-2.89 (m, 2H), 1.17 (t, 3H, *J* = 7.1 Hz), 1.06 (t, 3H, *J* = 7.1 Hz); ¹³C NMR (75 MHz, CDCl₃): δ = 149.3 (d, *J* = 5.6 Hz), 136.4 (d, *J* = 5.4 Hz), 130.6, 129.1 (2C), 128.7 (d, *J* = 2.3 Hz), 128.1 (d, *J* = 4.6 Hz), 127.4 (d, *J* = 3.4 Hz), 125.8 (d, *J* = 2.6 Hz), 118.5, 114.8 (2C), 63.3 (d, *J* = 7.2 Hz), 62.3 (d, *J* = 7.7 Hz), 58.8 (d, *J* = 159.3 Hz), 43.5, 26.7, 16.4 (d, *J* = 5.6 Hz), 16.3 (d, *J* = 6.0 Hz); ³¹P NMR (121 MHz, CDCl₃): δ = 22.1; IR (neat): ν = 3460, 2920, 2853, 1592, 1447, 1385, 1242, 1025, 961, 749 cm⁻¹; EI-MS: *m/z* = 346 (*M*⁺+1, 8%), 345 (*M*⁺, 37%), 208 (*M*⁺-PO(OEt)₂, 100%).


Diethyl 2-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 5b



was synthesized according to the general procedure (48h)

¹H NMR (400 MHz, CDCl₃): δ = 7.31-7.29 (m, 1H), 7.19-7.07 (m, 3H), 6.90-6.82 (m, 4H), 4.98 (d, 1H, *J* = 20.3 Hz), 4.02-3.81 (m, 5H), 3.49-3.44 (m, 1H), 3.01-2.84 (m, 2H), 1.17 (t, 3H, *J* = 7.1 Hz), 1.08 (t, 3H, *J* = 7.1 Hz); ¹³C NMR (100 MHz, CDCl₃): δ = 156.4 (d, *J* = 238.0 Hz), 146.1 (dd, *J* = 1.9, 6.6 Hz), 136.3 (d, *J* = 5.6 Hz), 130.4, 128.8 (d, *J* = 2.5 Hz), 128.1 (d, *J* = 4.5 Hz), 127.4 (d, *J* = 3.4 Hz), 125.9 (d, *J* = 2.9 Hz), 116.5 (d, *J* = 7.4 Hz), 115.4 (d, *J* = 22.1 Hz), 63.2 (d, *J* = 7.2 Hz), 62.3 (d, *J* = 7.6 Hz), 59.3 (d, *J* = 159.0 Hz), 44.3, 26.5, 16.4 (d, *J* = 5.6 Hz), 16.3 (d, *J* = 5.9 Hz); ³¹P NMR (121 MHz, CDCl₃): δ = 22.0; ¹⁹F NMR (376 MHz, CDCl₃): δ = -126.3; IR (neat): ν = 3445, 3019, 2924, 2854, 1712, 1441, 1384, 1215, 1027, 756 cm⁻¹; EI-MS: *m/z* = 364 (*M*⁺+1, 4%), 363 (*M*⁺, 17%), 226 (*M*⁺-PO(OEt)₂, 100%).

Diethyl 2-(4-bromophenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 5c




was synthesized according to the general procedure (96h)

¹H NMR (300 MHz, CDCl₃): δ = 7.29-7.23 (m, 3H), 7.15-7.11 (m, 3H), 6.79-6.76 (m, 2H), 5.03 (d, 1H, *J* = 19.2 Hz), 4.06-3.74 (m, 5H), 3.50-3.42 (m, 1H), 3.17-3.04 (m, 1H), 2.95-2.87 (m, 1H), 1.16 (t, 3H, *J* = 7.1 Hz), 1.07 (t, 3H, *J* = 7.1 Hz); ¹³C NMR (75 MHz, CDCl₃): δ = 148.3 (d, *J* = 4.7 Hz), 136.3, 131.8 (2C), 130.4, 128.6 (d, *J* = 2.6 Hz), 128.1 (d, *J* = 4.8 Hz), 127.6 (d, *J* = 3.2 Hz), 126.0 (d, *J* = 2.7 Hz), 116.1 (2C), 110.3, 63.2 (d, *J* = 7.4 Hz), 62.4

(d, $J = 7.6$ Hz), 58.7 (d, $J = 159.6$ Hz), 43.6, 26.9, 16.4 (d, $J = 7.0$ Hz), 16.3 (d, $J = 6.0$ Hz); ^{31}P NMR (121 MHz, CDCl_3): $\delta = 21.8$; IR (neat): $\nu = 3442, 3014, 2926, 2856, 1712, 1657, 1488, 1385, 1216, 1024, 756\text{ cm}^{-1}$; EI-MS: $m/z = 425$ ($\text{M}^+ + 2$, 4%), 423 (M^+ , 4%), 286 ($\text{M}^+ - \text{PO}(\text{OEt})_2$, 100%).


Diethyl 2-(4-ethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 5d



was synthesized according to the general procedure (48h)

^1H NMR (300 MHz, CDCl_3): $\delta = 7.32\text{--}7.28$ (m, 1H), 7.12–7.06 (m, 3H), 7.02–6.99 (m, 2H), 6.85–6.82 (m, 2H), 5.06 (d, 1H, $J = 20.7$ Hz), 4.07–3.80 (m, 5H), 3.57–3.50 (m, 1H), 2.94–2.90 (m, 2H), 2.48 (q, $J = 7.6$ Hz, 2H), 1.18 (t, 3H, $J = 7.1$ Hz), 1.11 (t, 3H, $J = 7.6$ Hz), 1.07 (t, 3H, $J = 7.1$ Hz); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 147.6$ (d, $J = 6.9$ Hz), 136.4 (d, $J = 5.6$ Hz), 134.5, 130.6, 128.8 (d, $J = 2.5$ Hz), 128.4 (2C), 128.1 (d, $J = 4.5$ Hz), 127.3 (d, $J = 3.5$ Hz), 125.8 (d, $J = 2.9$ Hz), 115.3 (2C), 63.3 (d, $J = 7.2$ Hz), 62.2 (d, $J = 7.6$ Hz), 59.1 (d, $J = 159.3$ Hz), 43.7, 27.8, 26.5, 16.5 (d, $J = 5.6$ Hz), 16.4 (d, $J = 6.0$ Hz), 15.8; ^{31}P NMR (121 MHz, CDCl_3): $\delta = 22.2$; IR (neat): $\nu = 3450, 3017, 2925, 2856, 1732, 1652, 1447, 1383, 1215, 1029, 757\text{ cm}^{-1}$; EI-MS: $m/z = 374$ ($\text{M}^+ + 1$, 3%), 373 (M^+ , 12%), 236 ($\text{M}^+ - \text{PO}(\text{OEt})_2$, 100%).


Diisopropyl 2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate¹ 7a



was synthesized according to the general procedure (72h)

^1H NMR (400 MHz, CDCl_3): $\delta = 7.34\text{--}7.31$ (m, 1H), 7.18–7.04 (m, 5H), 6.88 (d, 2H, $J = 8.3$ Hz), 6.69 (t, 1H, $J = 7.3$ Hz), 5.06 (d, 1H, $J = 21.2$ Hz), 4.59–4.51 (m, 2H), 4.02–3.95 (m, 1H), 3.61–3.55 (m, 1H), 2.96–2.90 (m, 2H), 1.22 (t, 6H, $J = 6.4$ Hz), 1.08 (d, 3H, $J = 6.2$ Hz), 0.87 (d, 3H, $J = 6.2$ Hz); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 149.5$ (d, $J = 6.6$ Hz), 136.4 (d, $J = 5.6$ Hz), 130.9 (d, $J = 1.4$ Hz), 129.0 (2C), 128.7 (d, $J = 2.6$ Hz), 128.4 (d, $J = 4.6$ Hz), 127.2 (d, $J = 4.6$ Hz), 125.6 (d, $J = 2.8$ Hz), 118.3, 115.1 (2C), 72.2 (d, $J = 7.8$ Hz), 70.8 (d, $J = 8.2$ Hz), 58.8 (d, $J = 164.9$ Hz), 43.5, 26.6, 24.6 (d, $J = 2.9$ Hz), 24.1 (d, $J = 3.2$ Hz), 23.7 (d, $J = 5.7$ Hz), 23.3 (d, $J = 5.6$ Hz); ^{31}P NMR (121 MHz, CDCl_3): $\delta = 22.0$; IR (neat): $\nu = 3467, 2978, 2924, 1597, 1499, 1460, 1381, 1243, 1107, 986, 750, 692, 566\text{ cm}^{-1}$; EI-MS: $m/z = 374$ ($\text{M}^+ + 1$, 3%), 373 (M^+ , 11%), 208 ($\text{M}^+ - \text{PO}(\text{OiPr})_2$, 100%).


Dibutyl 2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 8a



was synthesized according to the general procedure (72h)

^1H NMR (400 MHz, CDCl_3): δ = 7.31-7.29 (m, 1H), 7.19-7.06 (m, 5H), 6.90 (d, 2H, J = 8.3 Hz), 6.71 (t, 1H, J = 7.3 Hz), 5.12 (d, 1H, J = 19.9 Hz), 3.98-3.86 (m, 3H), 3.84-3.78 (m, 1H), 3.76-3.68 (m, 1H), 3.59-3.53 (m, 1H), 3.02-2.89 (m, 2H), 1.52-1.45 (m, 2H), 1.41-1.34 (m, 2H), 1.30-1.13 (m, 4H), 0.81 (t, 3H, J = 7.4 Hz), 0.74 (t, 3H, J = 7.4 Hz); ^{13}C NMR (100 MHz, CDCl_3): δ = 149.3 (d, J = 5.6 Hz), 136.3 (d, J = 5.6 Hz), 130.7, 129.1 (2C), 128.7 (d, J = 2.6 Hz), 128.1 (d, J = 4.6 Hz), 127.4 (d, J = 3.4 Hz), 125.8 (d, J = 2.7 Hz), 118.4, 114.8 (2C), 66.9 (d, J = 7.6 Hz), 65.9 (d, J = 8.0 Hz), 58.7 (d, J = 158.6 Hz), 43.4, 32.6 (d, J = 5.9 Hz), 32.5 (d, J = 6.1 Hz, 2C), 26.8, 18.6 (d, J = 6.2 Hz, 2C), 13.5 (d, J = 4.1 Hz, 2C); ^{31}P NMR (121 MHz, CDCl_3): δ = 23.3; IR (neat): ν = 3485, 2960, 2875, 2425, 1465, 1262, 1069, 1031, 977, 556 cm^{-1} . EI-MS: m/z = 402 ($\text{M}^+ + 1$, 5%), 401 (M^+ , 19%), 208 ($\text{M}^+ - \text{PO}(\text{O}^n\text{Bu})_2$, 100%).


Diphenyl 2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9a



was synthesized according to the general procedure (24h)

^1H NMR (300 MHz, CDCl_3): δ = 7.46-7.42 (m, 1H), 7.22-6.93 (m, 16H), 6.80-6.74 (m, 2H), 5.52 (d, 1H, J = 19.9 Hz), 4.03-3.94 (m, 1H), 3.62-3.55 (m, 1H), 2.97-2.95 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ = 150.7 (d, J = 10.4 Hz), 150.3 (d, J = 11.4 Hz), 149.2 (d, J = 6.9 Hz), 136.7 (d, J = 5.9 Hz), 129.6 (2C), 129.4 (2C), 129.3, 129.2 (2C), 129.0 (d, J = 2.6 Hz), 128.4 (d, J = 4.9 Hz), 127.9 (d, J = 3.7 Hz), 126.2 (d, J = 2.8 Hz), 125.0, 124.8, 120.6 (d, J = 4.1 Hz, 2C), 120.3 (d, J = 4.1 Hz, 2C), 119.1, 115.4 (2C), 59.1 (d, J = 160.6 Hz), 44.0, 26.6; ^{31}P NMR (121 MHz, CDCl_3): δ = 14.7; IR (neat): ν = 3462, 2920, 2852, 1736, 1586, 1448, 1384, 1188, 1025, 930, 756 cm^{-1} ; EI-MS: m/z = 442 ($\text{M}^+ + 1$, 5%), 441 (M^+ , 17%), 208 ($\text{M}^+ - \text{PO}(\text{OPh})_2$, 100%).

Diphenyl 2-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9b




was synthesized according to the general procedure (12h)

^1H NMR (300 MHz, CDCl_3): δ = 7.46-7.43 (m, 1H), 7.20-6.80 (m, 17H), 5.37 (d, 1H, J = 20.5 Hz), 4.03-3.94 (m, 1H), 3.52-3.44 (m, 1H), 2.92-2.87 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ = 156.8 (d, J = 238.6 Hz), 150.8 (d, J = 10.5 Hz), 150.2 (d, J = 11.0 Hz), 146.0 (dd, J = 2.0, 8.0 Hz), 136.8 (d, J = 6.2 Hz), 129.6 (2C), 129.5 (2C), 129.2, 129.1 (d, J = 2.6 Hz), 128.4 (d, J = 4.9 Hz), 128.0 (d, J = 3.7 Hz), 126.3 (d, J = 2.9 Hz), 125.0, 124.8, 120.6 (d, J = 4.2 Hz,

2C), 120.3 (d, $J = 4.1$ Hz, 2C), 117.5 (d, $J = 7.5$ Hz, 2C), 115.6 (d, $J = 22.2$ Hz, 2C), 59.6 (d, $J = 160.3$ Hz), 44.9, 26.3; ^{31}P NMR (121 MHz, CDCl_3): δ 14.4; ^{19}F NMR (376 MHz, CDCl_3): δ -125.1; IR (neat): $\nu = 3448, 2924, 2855, 1730, 1591, 1453, 1213, 1022, 934, 755, 689\text{ cm}^{-1}$; EI-MS: $m/z = 459$ (M^+ , 2%), 226 ($\text{M}^+ - \text{PO}(\text{OPh})_2$, 100%).


Diphenyl 2-(4-bromophenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9c



was synthesized according to the general procedure (16h)

^1H NMR (300 MHz, CDCl_3): $\delta = 7.44\text{--}7.41$ (m, 1H), 7.28–6.90 (m, 13H), 6.83–6.76 (m, 4H), 5.43 (d, 1H, $J = 19.1$ Hz), 3.98–3.89 (m, 1H), 3.54–3.46 (m, 1H), 3.08–3.02 (m, 1H), 2.96–2.87 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 150.6$ (d, $J = 10.5$ Hz), 150.2 (d, $J = 11.3$ Hz), 148.2 (d, $J = 5.8$ Hz), 136.5 (d, $J = 5.6$ Hz), 132.0 (2C), 129.6 (2C), 129.5 (2C), 129.3, 129.0 (d, $J = 2.6$ Hz), 128.4 (d, $J = 5.0$ Hz), 128.1 (d, $J = 3.6$ Hz), 126.4 (d, $J = 2.6$ Hz), 125.1, 124.9, 120.5 (d, $J = 4.1$ Hz, 2C), 120.2 (d, $J = 4.1$ Hz, 2C), 116.8 (2C), 111.1, 59.1 (d, $J = 160.7$ Hz), 44.1, 26.7; ^{31}P NMR (121 MHz, CDCl_3): $\delta = 14.2$; IR (neat): $\nu = 3444, 2921, 2852, 1732, 1589, 1487, 1384, 1267, 1187, 931, 758\text{ cm}^{-1}$; EI-MS: $m/z = 521$ (M^{+2} , 4%), 519 (M^+ , 3%), 286 ($\text{M}^+ - \text{PO}(\text{OPh})_2$, 100%).


Diphenyl 2-(4-ethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9d



was synthesized according to the general procedure (32h)

^1H NMR (300 MHz, CDCl_3): $\delta = 7.46\text{--}7.43$ (m, 1H), 7.20–6.93 (m, 13H), 6.90–6.79 (m, 4H), 5.46 (d, 1H, $J = 20.6$ Hz), 4.03–3.94 (m, 1H), 3.60–3.52 (m, 1H), 2.94–2.89 (m, 2H), 2.49 (q, 2H, $J = 7.6$ Hz), 1.12 (t, 3H, $J = 7.6$ Hz); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 150.8$ (d, $J = 10.6$ Hz), 150.3 (d, $J = 10.9$ Hz), 147.4 (d, $J = 7.6$ Hz), 136.8 (d, $J = 5.8$ Hz), 135.3, 129.6 (2C), 129.4 (2C), 129.1 (d, $J = 2.5$ Hz), 128.6 (2C), 128.4 (d, $J = 4.9$ Hz), 127.8 (d, $J = 3.7$ Hz), 126.1 (d, $J = 2.8$ Hz), 125.0, 124.8, 120.7 (d, $J = 4.1$ Hz, 2C), 120.4 (d, $J = 4.1$ Hz, 2C), 116.0 (2C), 115.3, 59.4 (d, $J = 160.6$ Hz), 44.3, 27.9, 26.4, 15.8; ^{31}P NMR (121 MHz, CDCl_3): $\delta = 14.8$; IR (neat): $\nu = 3329, 2925, 2855, 1730, 1593, 1488, 1214, 1024, 934, 755, 690\text{ cm}^{-1}$; EI-MS: $m/z = 469$ (M^+ , 4%), 236 ($\text{M}^+ - \text{PO}(\text{OPh})_2$, 100%).

Diphenyl 2-p-tolyl-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9e




was synthesized according to the general procedure (12h)

^1H NMR (300 MHz, CDCl_3): $\delta = 7.46\text{--}7.43$ (m, 1H), 7.18–6.94 (m, 13H), 6.87–6.80 (m, 4H), 5.44 (d, 1H, $J = 20.9$ Hz), 4.03–

3.94 (m, 1H), 3.59-3.51 (m, 1H), 2.93-2.88 (m, 2H), 2.19 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ = 150.8 (d, J = 10.4 Hz), 150.3 (d, J = 10.7 Hz), 147.24 (d, J = 8.1 Hz), 136.8 (d, J = 6.0 Hz), 131.2, 129.7 (2C), 129.6 (2C), 129.4 (2C), 129.1 (d, J = 2.4 Hz), 128.7, 128.4 (d, J = 4.8 Hz), 127.8 (d, J = 3.6 Hz), 126.1 (d, J = 2.9 Hz), 125.0, 124.8, 120.7 (d, J = 4.1 Hz, 2C), 120.4 (d, J = 4.1 Hz, 2C), 116.1 (2C), 59.4 (d, J = 160.9 Hz), 44.4, 26.3, 20.4; ^{31}P NMR (121 MHz, CDCl_3): δ = 14.8; IR (neat): ν = 3452, 3019, 2924, 2855, 1711, 1444, 1216, 757 cm^{-1} ; EI-MS: m/z = 455 (M^+ , 7%), 222 (M^+ -PO(OPh) $_2$, 100%).


Diphenyl 2-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9f



was synthesized according to the general procedure (12h)

^1H NMR (300 MHz, CDCl_3): δ = 7.48-7.44 (m, 1H), 7.20-6.95 (m, 11H), 6.88-6.83 (m, 4H), 6.75-6.72 (m, 2H), 5.32 (d, 1H, J = 21.9 Hz), 4.03-3.96 (m, 1H), 3.67 (s, 3H), 3.51-3.43 (m, 1H), 2.85-2.83 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ = 153.6, 151.0 (d, J = 10.5 Hz), 150.3 (d, J = 11.2 Hz), 143.9 (d, J = 9.8 Hz), 136.7 (d, J = 6.3 Hz), 129.6 (2C), 129.4 (2C), 129.2 (d, J = 2.4 Hz), 128.4 (d, J = 4.6 Hz), 127.8 (d, J = 3.6 Hz), 126.1 (d, J = 3.0 Hz), 125.0, 124.8, 120.7 (d, J = 4.2 Hz, 2C), 120.4 (d, J = 4.5 Hz, 2C), 118.6 (2C), 114.5 (2C), 59.8 (d, J = 160.4 Hz), 55.6, 45.4, 25.9; ^{31}P NMR (121 MHz, CDCl_3): δ = 14.6; IR (neat): ν = 3449, 2921, 2853, 1732, 1585, 1451, 1385, 1183, 958, 753 cm^{-1} ; EI-MS: m/z = 471 (M^+ , 8%), 238 (M^+ -PO(OPh) $_2$, 100%).


Diphenyl 2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9g



was synthesized according to the general procedure (20h)

^1H NMR (300 MHz, CDCl_3): δ = 7.44-7.41 (m, 1H), 7.17-6.93 (m, 12H), 6.81-6.78 (m, 2H), 6.63-6.56 (m, 1H), 6.51 (t, 1H, J = 2.3 Hz), 6.33 (dd, 1H, J = 2.3, 8.1 Hz), 5.51 (d, 1H, J = 19.8 Hz), 4.00-3.91 (m, 1H), 3.70 (s, 3H), 3.61-3.55 (m, 1H), 2.98-2.95 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ = 160.7, 150.6 (d, J = 7.0 Hz), 150.3 (d, J = 11.2 Hz), 136.7 (d, J = 5.6 Hz), 129.9, 129.6 (2C), 129.4 (2C), 129.0 (d, J = 2.6 Hz), 128.4 (d, J = 5.0 Hz), 128.0 (d, J = 3.5 Hz), 126.2 (d, J = 2.6 Hz), 125.1, 124.9, 120.6 (d, J = 4.1 Hz, 2C), 120.4 (d, J = 4.0 Hz, 2C), 120.0, 115.3, 108.2, 103.8, 102.1, 59.2 (d, J = 160.9 Hz), 55.2, 44.0, 26.7; ^{31}P NMR (121 MHz, CDCl_3): δ = 14.6; IR (neat): ν = 2924, 2853, 1734, 1590, 1488, 1251, 1191, 1162, 924, 755, 687 cm^{-1} ; EI-MS: m/z = 471 (M^+ , 3%), 238 (M^+ -PO(OPh) $_2$, 100%).


Diphenyl 2-(2-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9h



was synthesized according to the general procedure (22h)

^1H NMR (300 MHz, CDCl_3): δ = 7.53-7.49 (m, 1H), 7.18-7.07 (m, 7H), 7.03-6.77 (m, 10H), 5.49 (d, 1H, J = 21.0 Hz), 4.11-4.01 (m, 1H), 3.72 (s, 3H), 3.65-3.57 (m, 1H), 2.91-2.83 (m, 1H), 2.77-2.68 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ = 152.6, 150.7 (d, J = 10.5 Hz), 150.4 (d, J = 10.9 Hz), 139.6 (d, J = 8.4 Hz), 136.2 (d, J = 6.4 Hz), 130.1, 129.6, 129.4 (2C), 129.3 (2C), 128.5 (d, J = 4.2 Hz), 127.5 (d, J = 3.7 Hz), 125.8 (d, J = 3.3 Hz), 124.7, 124.6, 123.5, 122.1, 120.9, 120.6 (d, J = 4.1 Hz, 4C), 111.7, 59.1 (d, J = 147.7 Hz), 55.4, 44.8, 26.7; ^{31}P NMR (121 MHz, CDCl_3): δ = 16.1; IR (neat): ν = 3064, 2925, 1590, 1490, 1457, 1240, 1186, 1024, 924, 748, 689 cm^{-1} ; EI-MS: m/z = 472 ($\text{M}^+ + 1$, 2%), 471 (M^+ , 7%), 238 ($\text{M}^+ - \text{PO}(\text{OPh})_2$, 100%)


Diphenyl 2-*o*-tolyl-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9i



was synthesized according to the general procedure (36h)

^1H NMR (300 MHz, CDCl_3): δ = 7.57-7.53 (m, 1H), 7.18-7.10 (m, 8H), 7.03-6.78 (m, 9H), 5.10 (d, 1H, J = 25.1 Hz), 4.07-3.98 (m, 1H), 3.22-3.15 (m, 1H), 2.82-2.59 (m, 2H), 2.22 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ = 150.9 (d, J = 10.7 Hz), 150.5 (d, J = 10.6 Hz), 150.1 (d, J = 12.3 Hz), 137.0 (d, J = 6.8 Hz), 133.7, 131.3, 129.5 (5C), 129.3 (d, J = 1.5 Hz), 128.5 (d, J = 4.0 Hz), 127.5 (d, J = 3.7 Hz), 126.6, 126.1 (d, J = 3.2 Hz), 124.8, 124.7, 124.1, 122.7, 120.6 (d, J = 4.1 Hz, 2C), 120.4 (d, J = 4.2 Hz, 2C), 60.3 (d, J = 160.4 Hz), 45.9, 25.1, 18.0; ^{31}P NMR (121 MHz, CDCl_3): δ = 14.8; IR (neat): ν = 3064, 2924, 1591, 1487, 1271, 1186, 925, 754, 688 cm^{-1} ; EI-MS: m/z = 456 ($\text{M}^+ + 1$, 1%), 455 (M^+ , 5%), 222 ($\text{M}^+ - \text{PO}(\text{OPh})_2$, 100%).

Diphenyl 2-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9j




was synthesized according to the general procedure (48h)

^1H NMR (300 MHz, CDCl_3): δ = 7.70-6.50 (m, 5H), 7.20-6.94 (m, 14 H), 6.82-6.78 (m, 2H), 5.66 (d, 1H, J = 20.7 Hz), 4.15-4.07 (m, 1H), 3.79-3.71 (m, 1H), 3.01-2.96 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ = 150.8 (d, J = 10.6 Hz), 150.3 (d, J = 11.1 Hz), 147.0 (d, J = 7.3 Hz), 136.6 (d, J = 5.7 Hz), 134.6, 132.1, 129.6 (2C), 129.4 (2C), 129.2 (d, J = 2.4 Hz), 129.1, 128.5 (d, J = 4.9 Hz), 128.1, 128.0 (d, J = 3.7 Hz), 127.4, 126.6, 126.4, 126.3, 125.1, 124.9, 123.2, 120.6 (d, J = 4.1 Hz, 2C), 120.3 (d, J = 4.1 Hz, 2C), 118.2, 110.3, 59.1 (d, J = 159.9 Hz), 44.3, 26.5; ^{31}P NMR (121 MHz, CDCl_3): δ = 14.6; IR (neat): ν = 3415, 2921,

2852, 1736, 1627, 1592, 1488, 1386, 1213, 1189, 1004, 926, 754, 686 cm^{-1} ; EI-MS: m/z = 491 (M^+). 491 (M^+ , 3%), 258 (M^+ -PO(OPh)₂, 100%).


Diphenyl 2-(biphenyl-4-yl)-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9k



was synthesized according to the general procedure (26h)

¹H NMR (300 MHz, CDCl₃): δ = 7.50-7.44 (m, 5H), 7.35-7.30 (m, 2H), 7.22-6.93 (m, 15H), 6.82-6.79 (m, 2H), 5.60 (d, 1H, J = 19.4 Hz), 4.06-3.94 (m, 1H), 3.67-3.61 (m, 1H), 3.11-2.91 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ = 150.2, 148.5 (d, J = 6.2 Hz), 140.8, 136.7 (d, J = 5.9 Hz), 131.7, 129.6 (2C), 129.5 (2C), 129.0 (d, J = 2.4 Hz), 128.7 (2C), 128.4 (d, J = 5.3 Hz), 128.0 (d, J = 3.2 Hz), 127.8 (2C), 127.6, 127.3, 126.4 (3C), 126.3 (d, J = 2.5 Hz), 125.5, 125.1, 124.9, 120.6 (d, J = 4.2 Hz, 2C), 120.3 (d, J = 4.0 Hz, 2C), 115.4 (2C), 59.1 (d, J = 160.3 Hz), 43.9, 26.8; ³¹P NMR (121 MHz, CDCl₃): δ = 14.6; IR (neat): ν = 2921, 2853, 1737, 1593, 1487, 1380, 1213, 1190, 928, 756, 691 cm^{-1} ; EI-MS: m/z = 517 (M^+ , 5%), 284 (M^+ -PO(OPh)₂, 100%).

Diphenyl 6,7-dimethoxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-ylphosphonate 9l



was synthesized according to the general procedure (20h)

¹H NMR (300 MHz, CDCl₃): δ = 7.22-6.94 (m, 14H), 6.84-6.77 (m, 3H), 6.59 (s, 1H), 5.42 (d, 1H, J = 20.1 Hz), 4.04-3.95 (m, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 3.67-3.61 (m, 1H), 2.92-2.74 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ = 150.8 (d, J = 10.5 Hz), 150.4 (d, J = 11.1 Hz), 149.4 (d, J = 8.3 Hz), 148.7 (d, J = 3.6 Hz), 147.3 (d, J = 2.7 Hz), 129.7 (2C), 129.4 (2C), 129.2 (2C), 128.9 (d, J = 6.8 Hz), 125.1, 124.8, 120.7, 120.5 (d, J = 4.1 Hz, 2C), 120.4 (d, J = 4.1 Hz, 2C), 119.4, 116.0 (2C), 111.8 (d, J = 2.2 Hz), 111.1 (d, J = 3.9 Hz), 58.7 (d, J = 160.8 Hz), 56.0, 55.9, 44.0, 25.8; ³¹P NMR (121 MHz, CDCl₃): δ = 14.9; IR (neat): ν = 3330, 2919, 2853, 1738, 1593, 1460, 1376, 1189, 1091, 939, 754, 690 cm^{-1} ; EI-MS: m/z = 501 (M^+ , 1%), 268 (M^+ -PO(OPh)₂, 100%).

1. O. Baslé and C. J. Li, *Chem. Commun.* 2009, 4124-4126.

Copy of ^1H NMR, ^{13}C NMR, ^{31}P NMR and ^{19}F spectra for the products

